You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

Details for Patent: 7,230,098


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,230,098 protect, and when does it expire?

Patent 7,230,098 protects XALKORI and is included in two NDAs.

This patent has forty-six patent family members in thirty-two countries.

Summary for Patent: 7,230,098
Title:Aminoheteroaryl compounds as protein kinase inhibitors
Abstract: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-MET ##STR00001##
Inventor(s): Cui; Jingrong Jean (San Diego, CA), Bhumralkar; Dilip (San Diego, CA), Botrous; Iriny (San Diego, CA), Chu; Ji Yu (Fremont, CA), Funk; Lee A. (Oceanside, CA), Hanau; Cathleen Elizabeth (Chesterfield, MO), Harris; G. Davis (Chesterfield, MO), Jia; Lei (San Diego, CA), Johnson; Joanne (Guilderland, NY), Kolodziej; Stephen A. (Ballwin, MO), Kung; Pei-Pei (San Diego, CA), Li; Xiaoyuan (Sharon) (Los Altas, CA), Lin; Jason (Qishen) (San Diego, CA), Meng; Jerry Jialun (San Diego, CA), Nambu; Mitchell David (San Diego, CA), Nelson; Christopher G. (Fresno, CA), Pairish; Mason Alan (San Diego, CA), Shen; Hong (San Diego, CA), Tran-Dube; Michelle (La Jolla, CA), Walter; Allison (Rexford, NY), Zhang; Fang-Jie (Sunnyvale, CA), Zhang; Jennifer (Foster City, CA)
Assignee: Sugen, Inc. (South San Francisco, CA)
Application Number:10/786,610
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,230,098

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv XALKORI crizotinib CAPSULE, PELLETS;ORAL 217581-001 Sep 7, 2023 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pf Prism Cv XALKORI crizotinib CAPSULE, PELLETS;ORAL 217581-002 Sep 7, 2023 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pf Prism Cv XALKORI crizotinib CAPSULE, PELLETS;ORAL 217581-003 Sep 7, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.